Welcome to the e-CCO Library Archive!
P051
Chemokines CXCL17, CCL20, and the receptor CXCR5 are overexpressed in the colonic mucosa from patients with active ulcerative colitis: CXCL17 is a potential marker of histological remission
J. Yamamoto-Furusho*1, E. Iturriaga-Goyon2, G. Fonseca-Camarillo1
1IBD Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico, 2Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico
P052
Intestinal total bacteria concentration and translocation of bacteria in inflammatory bowel disease
S. Vrakas1, M. Gazouli*2, K. Mountzouris3, G. Michalopoulos1, G. Karamanolis4, G. Papatheodoridis5, C. Tzathas1
1Tzaneion General Hospital, Gastroenterology Department, Piraeus, Greece, 2Medical School, National & Kapodistrian University, Biology, Athens, Greece, 3Agriculture University, Nutritional Physiology and Feeding, Athens, Greece, 4Medical School, National & Kapodistrian University, Gastroenterology Unit, Second University Surgical Department, Athens, Greece, 5Medical School National & Kapodistrian University, Gastroenterology, Athens, Greece
P053
Histological and immunohistochemical indicators of progression towards malignancy in ulcerative colitis
C. Popp*1, G. Micu1, M. Cioplea1, L. Sticlaru1, G. Pop1, B. Mateescu2, F. Staniceanu1, S. Zurac1, L. Nichita1
1Colentina University Hospital, Pathology, Bucuresti, Romania, 2Colentina University Hospital, Gastroenterology, Bucuresti, Romania
P054
Soluble GPVI is raised in patients with inflammatory bowel disease and anaemia
S. J. Montague1, A. Chauhan*2, E. E. Gardiner3, R. K. Andrews3, S. P. Watson1, T. Iqbal4
1Institute of Biomedical Research, University of Birmingham, Centre for Cardiovascular Sciences, College of Medical and Dental Sciences, Birmingham, United Kingdom, 2Centre for Liver Research, and National Institute of Health Research Birmingham Liver Biomedical Research Unit, Institute of Biomedical Research, College of Medical and Dental Science, Birmingham, United Kingdom, 3Monash University, Australian Centre for Blood Diseases, Melbourne, Australia, 4Queen Elizabeth Hospital, Department of Gastroenterology, Birmingham, United Kingdom
P055
Galectin-3 plays protective roles in intestinal Behçet’s disease
J. H. Kim*1, 2, H. J. Lee1, H. W. Ma1, 2, D. H. Seo1, 2, X. Che1, 2, D. H. Kim1, S. W. Kim1, 2, 3, J. H. Cheon1, 2, 3
1Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, South Korea, 2Yonsei University, Brain Korea 21 Plus Project for Medical Science, Seoul, South Korea, 3Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea
P056
Evaluation of oxidative stress in experimental model of Chron’s disease under hyperbaric oxygen treatment
F. S. Nakutis1, I. Nishitokukado1, F. M. d. Santos1, C. Ortiz-Agostinho1, V. S. Nunes2, A. Zonetti1, A. Sipahi*1
1Faculdade de Medicina da USP, Gastroenterologia Lim07, São Paulo, Brazil, 2Universidade de Medicina da USP, Laboratório Lípides, São Paulo, Brazil
P057
HLA B27 transgenic rat: a new animal model of postsurgical ileitis in inflammatory bowel disease
A. Chau*1, C. Chater1, S. Speca2, M. Djouina2, C. Dubuquoy2, L. Dubuquoy2, C. Neut3, D. Koriche1, P. Zerbib1, F.R. Pruvot1, P. Desreumaux4, B. Pariente4
1Lille University North of France, INSERM U995, Department of Digestive Surgery and Transplantation, CHRU Lille, Lille, France, 2Lille University North of France, INSERM U995, CHRU Lille, Lille, France, 3Lille University North of France, INSERM U995, Department of Microbiology, Faculty of Pharmacy, Lille, France, 4Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille 2, Inserm Unit 995, University of Lille 2, Lille, France
P058
Bacterial activation of thioguanine results in lymphocyte independent improvement in murine colitis
I. Oancea1, 2, I. Das1, D. Aguirre de Cárcer3, R. Movva1, 4, V. Schreiber1, Y. Yang1, 5, M. Proctor1, R. Wang1, Y. Sheng1, M. Lobb1, P. Ó Cuiv6, J. A. Duley1, 4, J. Begun*2, 7, T. H. J. Florin1, 2
1University of Queensland, Mater Research Institute, Brisbane, Australia, 2University of Queensland, School of Medicine, Brisbane, Australia, 3CSIRO, Preventative Health National Research Flagship and Division of Livestock Industries, Brisbane, Australia, 4Griffith University, School of Pharmacy, Gold Coast, Australia, 5University of Queensland, School of Pharmacy, Brisbane, Australia, 6University of Queensland, Diamantina Institute, Brisbane, Australia, 7University of Queensland, Mater Research Institute, South Brisbane, Australia
P059
Two new genetic mouse models for ulcerative colitis based on lateral tight junction disruption.
W. Stremmel*1, S. Staffer2, M. Schneider3, H. Gan-Schreier2, A. Wannhoff2, A. Gauss4, H. Wolburg5, M. Bach6, A. Swidsinski7, T. Efferth3
1University Hospital of Heidelberg, Internal Medicine IV, Dept. of Gastroenterology, Heidelberg, Germany, 2University Hospital of Heidelberg, Internal Medicine IV, Div. of Gastroenterology, Heidelberg, Germany, 3Johannes Gutenberg University, Institute of Pharmacy & Biochemistry, Mainz, Germany, 4University Hospital of Heidelberg, Gastroenterology, Heidelberg, Germany, 5University Medical School Tuebingen, Pathology and Neuropathology, Tuebingen, Germany, 6Kirchhoff Institute of Physics, Physics, Heidelberg, Germany, 7Charité - University Hospital Berlin, Berlin, Germany
P060
Alterations of brain structure in Crohn’s disease with extraintestinal manifestations
A. Thomann*1, W. Reindl2, P. Thomann3, C. Wolf4, D. Hirjak3, M. Griebe5
1Universitätsmedizin Mannheim, Department of Medicine II, Mannheim, Germany, 2Universitätsmedizin Mannheim, Department of Medicine II, Mannheim, Germany, 3Universitätsklinik Heidelberg, Department of Psychiatry, Heidelberg, Germany, 4Universität des Saarlandes, Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, Homburg/Saar, Germany, 5Universitätsmedizin Mannheim, Department of Neurology, Mannheim, Germany
P061
Creeping fat contains a unique T-cell compartment with potential impact on intestinal inflammation
L. I. Kredel*1, L. J. Jödicke1, A. A. Kuehl1, I. Freise1, J. Gröne2, B. Siegmund1
1Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Gastroenterology, Infectiology and Rheumatology, Berlin, Germany, 2Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, General, Vascular and Thoracic Surgery, Berlin, Germany
P062
Critical role of the IL-33/ST2 axis in colitis-associated colorectal cancer
L. R. Lopetuso*1, 2, 3, C. De Salvo3, L. Di Martino3, W. Goodman3, F. Scaldaferri2, A. Gasbarrini2, T. T. Pizarro3
1Catholic University of the Sacread Hearth, Internal Medicine, Gastroenterology Division, Rome, Italy, 2Catholic University of Sacred Heart, Internal Medicine Department, Gastroenterology Division, Rome, Italy, 3Case Western Reserve University, Pathology, Cleveland, United States
P063
Dissecting the role of rage in intestinal fibrosis
S. Speca*1, M. Body-Malapel1, C. Fradin1, M. Djouina1, E. Boulanger1, A.-M. Schmidt2, P. Desreumaux1, C. Vignal1
1Centre Hospitalier Régional Universitaire de Lille, Lille, France, 2NYU Langone Medical Centre, Departments of Medicine (Endocrinology Div), Biochemistry and Molecular Pharmacology and Pathology (Pathology) , New York, United States
P064
TOP1210 narrow spectrum kinase inhibitor demonstrates superior activity and improved safety profile potential compared with corticosteroid and immunomodulators in preclinical models of colitis
C. A. Walshe*, A. Rowley, M. R. Foster, Y. Solanke, S. Sirohi, M. C. Fyfe, S. Webber
Topivert Pharma Ltd, London, United Kingdom
P065
Molecular landscape of early Crohn’s disease using an integrated approach of mRNA/miRNA profiling and genomics
S. Verstockt*1, J. Van der Goten2, M. Vancamelbeke2, B. Verstockt2, F. Schuit3, P. Rutgeerts2, M. Ferrante2, S. Vermeire2, I. Arijs2, I. Cleynen1
1KU Leuven, Department of Human Genetics, Leuven, Belgium, 2KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Centre for Gastrointestinal Disorders, Leuven, Belgium, 3KU Leuven, Department of Cellular and Molecular Medicine, Gene Expression Unit, Leuven, Belgium
P066
CCR2-monocytes are essential for the resolution of inflammation and tissue repair in colitis.
M. Stakenborg, G. Goverse, G. Farro, P. J. Gomez-Pinilla, G. E. Boeckxstaens, G. Matteoli*
KU Leuven, P.O. Box 701, Department of Clinical and Experimental Medicine, Leuven, Belgium
P067
Angiogenic characterisation of Crohn’s disease mesenteric adipose tissue
M. Eddama*1, R. Cohen1, M. Rodriguez-Justo2, I. Evans3, L. Shen4, L. Clapp4, M. Loizidou5
1University College London Hospital, Colorectal Surgery, London, United Kingdom, 2University College London Hospital, Department of Pathology, London, United Kingdom, 3University College London, Centre for Cardiovascular Biology and Medicine, London, United Kingdom, 4University College London, Institute of Cardiovascular Science, London, United Kingdom, 5University College London, Academic Department of Surgery, London, United Kingdom
P068
Anti-fibrotic therapy for Crohn’s disease: in-vitro proof of concept with a selective ROCK2 inhibitor, LYC-53976, in the treatment of human intestinal myofibroblasts in stiffness and transforming growth factor β models
E. Rodansky1, X. Liu2, L. A. Johnson1, K. Demock2, A. J. Celeste2, L. L. Carter2, P. D. R. Higgins*1
1University of Michigan, Internal Medicine - Gastroenterology, Ann Arbor, Michigan, United States, 2Lycera, Inc., Ann Arbor, Michigan, United States
P069
TD-1473, a novel, potent, and orally administered, GI-targeted, pan-Janus kinase (JAK) inhibitor
D. Beattie*, P. Tsuruda, F. Shen, P. Brassil, C. Langrish, J. Janc, Z. Ren, R. Hudson, J. Smith, S. Hegde
Theravance Biopharma, South San Francisco, United States
P070
The influence of vitamin D on M1 and M2 macrophages in patients with Crohn’s disease
E. Seidman*, S. Dionne
Research Institute of the McGill University Hospital, Gastroenterology, Montreal, Canada